Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Primary |
Time until relapse |
Time (in days) until relapse during the observation period |
12 months after delivery compared to baseline |
|
Secondary |
Number of T2 lesions |
Number of T2 lesions in spinal and cerebral magnetic resonance imaging |
12 months after delivery compared to baseline |
|
Secondary |
Number of gadolinium enhancing lesions |
Number of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging |
12 months after delivery compared to baseline |
|
Secondary |
Volume of T2 lesions |
Volume of T2 lesions in spinal and cerebral magnetic resonance imaging |
12 months after delivery compared to baseline |
|
Secondary |
Volume of gadolinium enhancing lesions |
Volume of gadolinium enhancing lesions in spinal and cerebral magnetic resonance imaging |
12 months after delivery compared to baseline |
|
Secondary |
Change in immune cell phenotypes |
Change in immune cell phenotypes of peripheral blood mononuclear cells (PBMC) |
12 months after delivery compared to baseline |
|
Secondary |
Galectin-1 |
Change in serum galectin-1 concentration measured by ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Galectin-3 |
Change in serum galectin-3 concentration measured by ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Galectin-9 |
Change in serum galectin-9 concentration measured by ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Neurofilament (NfL) |
Change in neurofilament serum concentration by using Simoa NfL assay |
12 months after delivery compared to baseline |
|
Secondary |
Pro-inflammatory interleukin-17 |
Change in interleukin-17 serum concentration assessed by ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Anti-inflammatory interleukin-10 |
Change in anti-inflammatory interleukin-10 serum concentration assessed by ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Autoantibody profiling |
Identification and quantification of autoantibodies by using protein microarray and ELISA |
12 months after delivery compared to baseline |
|
Secondary |
Fecal microbiome composition |
Composition of fecal microbiome measured by 16S Sequencing |
12 months after delivery compared to baseline |
|
Secondary |
Thickness of the retinal nerve fibre layer |
Thickness of the retinal nerve fibre layer by Optical Coherence Tomography (OCT) |
12 months after delivery (compared to baseline) |
|
Secondary |
Total macular volume (TMV) |
Total macular volume by Optical Coherence Tomography (OCT) |
12 months after delivery compared to baseline |
|
Secondary |
Mini-International Neuropsychiatric Interview (M.I.N.I.) German Version 5.0.0 Module A-C |
Structured diagnostic interview to assess depression, dysthymia and suicidality |
12 months after delivery compared to baseline |
|
Secondary |
Montgomery-Asberg Depression Rating Scale (MADRS) |
Rating of ten depression related symptoms on a scale from 0 to 6 (higher numbers indicate more severe symptoms) |
12 months after delivery compared to baseline |
|
Secondary |
Beck Depression Inventory (BDI-II) |
Rating of 21 depression related symptoms on a scale from 0 to 3 (higher numbers indicate more severe symptoms) |
12 months after delivery compared to baseline |
|
Secondary |
Edinburgh Postpartum Depression Scale (EPDS) |
Self-report survey containing 10 items, each item is rated 0-3 (higher scores indicate a higher probability of postpartum depression) |
12 months after delivery compared to baseline |
|
Secondary |
Modified Fatigue Inventory Scale (MFIS) |
Self-report survey containing 21 items, each item is rated 0-4 (higher scores indicate a greater impact of fatigue on a person's activities) |
12 months after delivery compared to baseline |
|
Secondary |
Fatigue Severity Scale (FSS) |
A self-report survey consisting of 11 items, each item ranges from 1 to 7 (higher scores indicate higher levels of fatigue) |
12 months after delivery compared to baseline |
|
Secondary |
Visual Fatigue Analogue Scale (VFAS) |
A self-administered, single scale indication measuring visual fatigue, ranging from 0 to 100 (higher scores indicate worse fatigue) |
12 months after delivery compared to baseline |
|
Secondary |
Short-Form Health Survey (SF-36) |
A self-report survey measuring health in eight dimensions (higher scores indicate less disability) |
12 months after delivery compared to baseline |
|